Prelude Reports Positive Data For PRT2527 In Lymphoid Malignancies

Prelude Therapeutics Incorporated is a clinical-stage precision oncology company. Today, the first interim results from its ongoing open-label, dose-escalation trial of PRT2527, a highly selective CDK9 inhibitor, have been announced. The data was presented at the 66th American Society of Hematology Annual Meeting in San Diego. The presentation elaborated on the drug's effectiveness as a monotherapy and combined it with zanubrutinib for patients with relapsed or refractory lymphoid malignancies.

Jane Huang, M.D., President and Chief Medical Officer of Prelude, said in a statement, “CDK9 has long been considered a potential therapeutic approach for treating hematologic malignancies and a highly selective CDK9 inhibitor was sought to minimise off-target toxicity. We are encouraged by the results demonstrated to date by PRT2527 both as a monotherapy and particularly in combination with zanubrutinib, resulting in an overall response rate of 38.5%, including two patients with aggressive lymphomas who had received prior CAR-T therapy. These results represent a positive step for CDK9 inhibition as a possible future therapeutic approach for patients with aggressive hematologic cancers with limited treatment options.”

As of September 17, 2024, 46 patients were enrolled, treated, and evaluated for safety. The results indicated that PRT2527 was generally well-tolerated across four dosing cohorts when utilized alone and three cohorts in combination with zanubrutinib. Both treatment approaches showed an acceptable safety profile and preliminary signs of effectiveness, even in patients who had previously undergone CAR-T therapy.